Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CAR-T
Biotech
Biotech shares first data for in vivo CAR-T that attracted AZ
Two patients had all signs of their multiple myeloma disappear completely after treatment, while two others saw partial responses to the cell therapy.
Darren Incorvaia
Jul 7, 2025 2:27pm
Oncternal sells cancer assets to mystery biotech, winds down ops
Jul 1, 2025 9:38am
AbbVie inks $2.1B Capstan buyout to enter in vivo CAR-T market
Jun 30, 2025 9:45am
Fierce Pharma
BioNTech to wind down cell therapy manufacturing in Maryland
Jun 18, 2025 10:23am
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Jun 13, 2025 1:22pm
ASCO: Kite's CAR-T flies high in phase 1 B-cell lymphoma study
May 31, 2025 7:00pm